A5050732025- Asthma and respiratory diseases
- Eosinophilic Esophagitis
- Respiratory and Cough-Related Research
- Eosinophilic Disorders and Syndromes
- Allergic Rhinitis and Sensitization
- Pediatric health and respiratory diseases
- Voice and Speech Disorders
- Dysphagia Assessment and Management
- Pharmaceutical studies and practices
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Thyroid Disorders and Treatments
- Inhalation and Respiratory Drug Delivery
- Pulmonary Hypertension Research and Treatments
- IL-33, ST2, and ILC Pathways
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Systemic Sclerosis and Related Diseases
- Bone health and treatments
- Medical Imaging and Pathology Studies
- Regulation of Appetite and Obesity
- Nutritional Studies and Diet
- Thyroid Cancer Diagnosis and Treatment
- Growth Hormone and Insulin-like Growth Factors
- Cutaneous lymphoproliferative disorders research
- Plant-based Medicinal Research
- Vascular Anomalies and Treatments
Bellus Health (Canada)
2021-2024
Teva Pharmaceuticals (United States)
2016-2020
University of Florida
2020
Columbus Oncology and Hematology Associates
2020
Teva Pharmaceuticals (Hungary)
2017
University of Pennsylvania
2013-2016
Hospital Universitario Ramón y Cajal
2012
Washington University in St. Louis
2007-2009
Hospital of the University of Pennsylvania
2009
IL-5, a mediator of eosinophil activity, is an important potential treatment target in patients with uncontrolled asthma. The efficacy reslizumab, humanized anti-human IL-5 monoclonal antibody, has been characterized blood eosinophils ≥ 400 cells/μL. This study further characterizes the and safety reslizumab poorly-controlled asthma, particularly those < cells/μL.Patients were randomly assigned to intravenous 3.0 mg/kg or placebo once every 4 weeks for 16 weeks. primary end point was change...
BackgroundIn placebo-controlled trials, reslizumab, an anti-IL-5 monoclonal antibody, significantly reduced asthma exacerbations and improved lung function control in patients with eosinophilic asthma.ObjectiveThis open-label extension study evaluated safety efficacy of reslizumab for up to 24 months.MethodsAfter participation 1 3 placebo-controlled, phase III trials moderate-to-severe asthma, received 3.0 mg/kg intravenously every 4 weeks months. Adverse events (AEs), function,...
To determine factors that influence 6-minute walk distance (6MWD) in patients with scleroderma (systemic sclerosis, SSc)-interstitial lung disease (ILD), SSc-pulmonary hypertension (PH), and idiopathic pulmonary fibrosis (IPF).We retrospectively evaluated all SSc or IPF who performed a test (6MWT) at university hospital between 1999 2003. Chi-square, ANOVA, simple linear regression, backwards elimination multivariable regressions were performed.Forty-eight consecutive 6MWT compared to 33...
Subclinical thyroid dysfunction is common in the elderly, yet its relationship with hip fracture and bone mineral density (BMD) unclear. We examined association between endogenous subclinical hyper- hypothyroidism BMD older adults. A total of 4936 US individuals 65 years old or enrolled Cardiovascular Health Study not taking preparations were included. Analyses incident performed by status, over a median follow-up 12 years. cross-sectional analysis status was subset 1317 participants who had...
Rationale: There is no broadly accessible treatment for patients with refractory chronic cough, a disease characterized by cough that persists despite other cough-related etiologies or has identified underlying cause. Objectives: SOOTHE (NCT04678206), Phase 2b, randomized, placebo-controlled trial, evaluated the efficacy and safety of P2X3 antagonist camlipixant in adults (cough duration ≥1 year; baseline awake frequency ≥25 coughs/hour). Methods: After single-blind, 16-day placebo run-in,...
BackgroundReslizumab displays efficacy in patients with inadequately controlled eosinophilic asthma; previous reports oral corticosteroid–dependent asthma are limited.ObjectiveTo assess of reslizumab and benefits on corticosteroid burden.MethodsWe report post hoc analyses pooled data from duplicate, placebo-controlled phase 3 trials. Patients aged 12 to 75 years controlled, moderate-to-severe were randomized 1:1 receive intravenous 3.0 mg/kg or placebo every 4 weeks for 52 weeks, stratified...
Background:Subclinical hypothyroidism is common in the elderly, yet its relationship with weight and body composition unclear.
Reslizumab is a humanized anti-IL-5 monoclonal antibody used as add-on maintenance treatment for patients with uncontrolled eosinophilic asthma.To predict response and nonresponse to intravenous reslizumab at 52 weeks an algorithm we developed based on clinical indicators from pivotal trials.Patients aged 18 years older who met Global Initiative Asthma 4 or 5 criteria received (n = 321) in two trials ( www.clinicaltrials.gov identifiers, NCT01287039 NCT01285323) were selected the data...
What is the key question?► How beneficial reslizumab in patients with severe refractory asthma?What bottom line?► Reslizumab provides significant clinical benefit and well tolerated asthma elevated blood eosinophil counts. Why read on?► This post hoc analysis first evidence that resulted exacerbations, lung function, control symptoms, quality of life for levels, which was consistent prior studies eosinophilia.on July 17,
A post hoc analysis of two randomized, placebo-controlled, Phase 3 trials intravenous reslizumab, an anti-interleukin-5 (IL-5) biologic for severe eosinophilic asthma.Relationships between baseline blood eosinophil levels (EOS), forced expiratory volume in 1 s (FEV1) reversibility to β2-agonists and treatment outcomes were assessed.Mean FEV1 was numerically lower among patients with high (≥ 400 cells/µL) versus low EOS. Reslizumab produced clinically significant improvement FEV1,...